Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 13/20 | 0.74 |
| ▸ | GFER | P55789 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23043967 | 0.87 | ACMSD (0.64) | ACMSDGFERLMNAHPGDHTT | |
| SCHEMBL17550089 | 0.85 | ACMSD (1.00) | ACMSDGFERTSHRKDM4E | |
| SCHEMBL17548492 | 0.77 | ACMSD (1.00) | ACMSDRAB9A | |
| SCHEMBL17548488 | 0.77 | ACMSD (1.00) | ACMSDRAB9A | |
| SCHEMBL17548458 | 0.77 | HPGD (0.69) | ACMSDGFERTSHRLMNAHPGD | |
| SCHEMBL32688002 | 0.76 | ACMSD (0.70) | ACMSDHTTSMN1; SMN2RAB9A | |
| SCHEMBL23050907 | 0.76 | LMNA (0.61) | ACMSDGFERLMNAHPGDHTT | |
| SCHEMBL17548489 | 0.75 | ACMSD (1.00) | ACMSDGFERTSHRLMNAHTT | |
| SCHEMBL24087924 | 0.75 | ACMSD (0.75) | ACMSDGFERTSHRKDM4E | |
| SCHEMBL31053417 | 0.75 | ACMSD (0.75) | ACMSDGFERTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362185-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2017-12-21 | — | — | US | disclosed |
| US-9708272-B2 | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2017-07-18 | — | — | US | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885GFER 596/4885TSHR 4829/4885 |
| US-20170362185-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ACMSD 1/4885GFER 596/4885TSHR 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.